ISRCTN15683590已完成不适用
Pilot, open-label, observational, prospective study to evaluated the clinical effect of chondroitin sulfate adjunctive therapy in patients with periodontitis
Rheumatology Service, Hospital del Mar0 个研究点目标入组 20 人开始时间: 2015年1月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Patients > 40 years
- •2. Fulfilled the American College of Rheumatology classification criteria for clinical knee, hand or hip OA
- •3. Initiated CS treatment for their OA
- •4. Had PD of any severity grade as assessed by the Community Periodontal Index Treatment Needs (CPITN)
- •5. Had PD of grades II, III or IV as assessed with the Löe and Silness gingival index
排除标准
- •1. Uncompensated cardiopathy;
- •2. Impaired renal or liver function;
- •3. Uncompensated asthma; severe infection
- •4. Human Immunodeficiency Virus
- •5. History of alcohol or substance abuse
- •6. Any currently uncompensated psychiatric disorder
- •7. Fibromyalgia
- •8. Uncompensated thyroid disease
- •9. Having a contraindication to CS use
研究者
相似试验
已完成
不适用
Study to evaluate the effect of chondroitin sulfate on the synovitis in patients with knee osteoarthritisMusculoskeletal DiseasesOsteoarthritisISRCTN64282813Hospital del Mar (Spain)70
进行中（未招募）
1 期
A pilot, prospective, randomized, open-label, blinded endpoint (PROBE) histopathology trial to assess the effects of ACE- inhibition therapyin preventing the evolution of proliferative lesions assessed by renal biopsy in patients with extracapillary glomerulonephritisEUCTR2015-003884-12-ITAZIENDA OSPEDALIERA PAPA GIOVANNI XXIII22
已完成
2 期
Antibiotic drop instillation during continuous contact lens wear.ACTRN12608000626369CIBA VISION Corporation40
尚未招募
不适用
A pilot study in a single center for comparison of stone-fragmentation rate of ESWL (extracorporeal shock-wave lithotripsy) with ElectroHydraulic (EH) method between foreign and domestic products.Diseases of The genitoruinary systemKCT0005298HNT Medical56
已完成
不适用
CLBS12-P01Patients with critical limb ischemia (CLI) due to arteriosclerosis obliterans (ASO) and patients with CLI due to Buerger's Disease (BD)JPRN-jRCT1080223694EPS Corporation (Global Sponsor: Caladrius Biosciences, Inc.)35